A Retrospective, Single-Center, Non-Randomized, Cross-Sectional Comparative Effectiveness Study Evaluating Surface Area Reduction, Volume Reduction and Closure Rates in Acute and Chronic Wounds Managed with Grafix® versus EpiFix®

Trial Profile

A Retrospective, Single-Center, Non-Randomized, Cross-Sectional Comparative Effectiveness Study Evaluating Surface Area Reduction, Volume Reduction and Closure Rates in Acute and Chronic Wounds Managed with Grafix® versus EpiFix®

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jan 2017

At a glance

  • Drugs Placental-derived mesenchymal stem cell therapy Osiris Therapeutics (Primary) ; DHACM
  • Indications Wounds
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jan 2017 According to Osiris Therapeutics media release, the study and results have been published in the peer-reviewed journal Wound Repair and Regeneration.
    • 06 May 2016 New trial record
    • 03 May 2016 According to MiMedx media release, this study does not meet any of the established criteria. As this study lacks an adequate or relevant controls and inadequate clinical study standards.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top